# Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy

> **NCT01079780** · PHASE2 · COMPLETED · sponsor: **Eastern Cooperative Oncology Group** · enrollment: 136 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **BIOLOGICAL:** cetuximab
- **BIOLOGICAL:** ramucirumab
- **DRUG:** irinotecan hydrochloride

## Key facts

- **NCT ID:** NCT01079780
- **Lead sponsor:** Eastern Cooperative Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01-18
- **Primary completion:** 2021-02-22
- **Final completion:** 2021-08-17
- **Target enrollment:** 136 (ACTUAL)
- **Last updated:** 2023-06-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01079780

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01079780, "Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01079780. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*